Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.

The company makes no secret of the need for durability with its anti-CD47 project SL-172154.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.